Pimarane cyclooxygenase 2 (COX-2) inhibitor and its structure-activity relationship

被引：29
|
作者：
Suh, YG
Kim, YH
Park, MH
Choi, YH
Lee, HK
Moon, JY
Min, KH
Shin, DY
Jung, JK
Park, OH
Jeon, RA
Park, HS
Kang, SA
机构：
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Chungnam Univ, Coll Pharm, Taejon 305764, South Korea
[3] Univ Ulsan, Coll Med, Seoul 138040, South Korea
[4] Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2001年 / 11卷 / 04期
关键词：
D O I：
10.1016/S0960-894X(01)00004-X
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The structure-activity relationship and molecular modelings of a novel pimarane COX-2 inhibitor are reported. Particularly, a series of linker extended analogues designed on the basis of these studies exhibited significantly enhanced COX-2 inhibitory activities and selectivities. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：559 / 562
页数：4
相关论文
共 50 条
  • [31] Selective cyclooxygenase-2 (COX-2) inhibitor. Belief, reality and hope
    Brune, K
    ORTHOPADE, 1997, 26 (09): : 804 - 806
  • [32] The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition
    Singh-Ranger, G
    Mokbel, K
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (07): : 729 - 737
  • [33] Development of an activity-based probe for cyclooxygenase-2 (COX-2)
    Yadav, Anuj
    Reinhardt, Christopher
    Chan, Jefferson
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [34] Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors
    Groesch, Sabine
    Maier, Thorsten Juergen
    Schiffmann, Susanne
    Geisslinger, Gerd
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (11): : 736 - 747
  • [35] Discovery and Structure-Activity Relationship of a Ryanodine Receptor 2 Inhibitor
    Ishida, Ryosuke
    Zeng, Xi
    Kurebayashi, Nagomi
    Murayama, Takashi
    Mori, Shuichi
    Kagechika, Hiroyuki
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2024, 72 (04) : 399 - 407
  • [36] Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398
    Yu, HP
    Shi, LY
    Lu, WH
    Su, YH
    Li, YY
    Xu, SQ
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (06) : 638 - 642
  • [37] Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: Design, synthesis, and structure-activity relationship
    Hayashi, Shigeo
    Sumi, Yoko
    Ueno, Naomi
    Murase, Akio
    Takada, Junji
    BIOCHEMICAL PHARMACOLOGY, 2011, 82 (07) : 755 - 768
  • [38] Cyclooxygenase-2 (Cox-2) in Newborn Lung
    P Lassus
    H Wolff
    S Andersson
    Pediatric Research, 1999, 45 (6) : 887 - 887
  • [39] COX-2 and its inhibitor Celecoxib in corneal neovascularization
    Dong, Yuan
    Zhang, Ming-Chang
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2008, 1 (01) : 13 - 17
  • [40] Cancer and cyclooxygenase-2 (COX-2) inhibition
    Evans, JF
    Kargman, SL
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (06) : 627 - 634
12345